错配切割修复蛋白表达与非小细胞肺癌术后辅助化疗效果的关系  

Relationship between ERCC1 expression and survival of resected patients with non-small cell lung cancer in adjuvant chemotherapy

作　　者：彭丽君[1,2] 曾伟生[1,2] 乔贵宾[1,2] 蒋仁超[1,2] 庞大志[1,2] 彭秀凡[1,2] 吴一龙[3,4,5] 

机构地区：[1]广州军区广州总医院胸外科 [2]广东省肺癌研究所临床中心,广州510010 [3]广东省人民医院 [4]广东省医学科学院 [5]广东省肺癌研究所,广州510080

出　　处：《广东医学》2010年第11期1396-1399,共4页Guangdong Medical Journal

基　　金：广东省自然科学基金资助项目(编号:06019699)

摘　　要：目的研究非小细胞肺癌患者肿瘤组织内错配切割修复蛋白(excision repair cross complement-1,ERCC1)的表达及其与含铂方案辅助化疗疗效的关系。方法收集在胸外科手术治疗并以含铂方案辅助化疗、符合一定纳入标准的非小细胞肺癌患者。利用组织芯片技术及免疫组化方法检测ERCC1在标本中的表达,分析ERCC1表达水平与临床病理特征以及综合治疗后总生存的关系。结果 ERCC1阳性表达率为54%,阴性组与阳性组平均生存期分别为45.6个月和33.6个月,中位生存期分别为39.0个月和24.0个月(P=0.044)。ERCC1在腺癌中出现高表达的频率明显高于鳞癌(P=0.035)。结论 ERCC1的表达情况可能是预测非小细胞肺癌含铂方案辅助化疗效果的重要因子。Objective To study the relationship between ERCC1 expression and efficacy of platinum-based adjuvant chemotherapy in patients with non-small cell cancer and to provide new clues for personalized therapy to individual NSCLC patients.Methods Seventy-four patients with NSCLC who underwent surgery and platinum based adjuvant chemotherapy between December 2000 and October 2006 in Department of Thoracic Surgery of Liuhuaqiao Hospital were recruited.Their corresponding tumor specimens,clinicopathological and survival data were collected as well.All specimens were used for construction of tissue microarry.The expression of ERCC1 was detected by immunohistochemistry and correlated with clinicopathological and survival data by（2 text and Kaplan-Meier survival curve.Results A positive nuclear staining for ERCC1 was observed in 40 patients,and the positive rate of ERCC1 was 54%.The mean and median survival times were 45.6 months and 39.0 months in ERCC1 negative patients,respectively,and were 33.6 months and 24.0 months in ERCC1 positive group,respectively（P=0.044）.It revealed that high level expression of ERCC1 was significantly more frequent in adencarcinoma than in squamous cell carcinoma（P=0.035）.Conclusion It suggests that the expression of ERCC1 may have predicting value on the efficacy of platinum based chemotherapy in patients with radically resected NSCLC.These findings may provide new clues for personalized therapy to individual NSCLC patients.

关 键 词：ERCC1 肺癌 预后 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]